– UK, Burton on Trent – Clinigen Group plc (AIM: CLIN), the global specialty pharmaceuticals business, announces that upon completion earlier today of the acquisition of Link Healthcare Private Limited, John Bacon joined the Group as a Non-Executive Director. Johannes Willemse will act as John Bacon’s alternate on the Clinigen board.
Mr Bacon founded Link in 1997 thereby pioneering the supply of specialist pharmaceuticals in the Australian market. He served as Executive Chairman of Link before its acquisition by Clinigen. Prior to forming Link, John held senior positions in the pharmaceutical industry across the Asia-Pacific region.
Mr Willemse has over 25 years of experience in the pharmaceutical industry. He served as Chief Executive Officer of Link prior to its acquisition by Clinigen.
Peter Allen, Chairman, Clinigen, said: “On behalf of the Board, I welcome John to the team and I am pleased that Johannes has agreed to act as his alternate. Our strategic acquisition of Link has strengthened both Clinigen’s international distribution network across the AAA region – Asia, Africa and Australasia – as well as our management team. Together, we can better meet the growing demand for much needed, but not always licensed, medicines across the world.”
About Clinigen Group
Clinigen Group is a global pharmaceutical and services company with a unique business model dedicated to delivering the right drug to the right patient at the right time. The Group consists of four synergistic businesses that provide medicines to patients with unmet medical need; Clinigen CTS manages the supply of commercial medicines for clinical trials; Idis Managed Access runs early access programs for Clinigen’s own and other companies’ portfolios; Idis Global Access works directly with healthcare providers to enable ethical compliant access to unlicensed medicines and Clinigen SP acquires and markets our own portfolio of hospital only niche medicines.
Clinigen is the global leader in ethically sourcing and supplying unlicensed medicines to hospital pharmacists and physicians for patients with a high unmet need.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
Comments are closed.